{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DLT&page=2", "query": { "intervention": "DLT", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DLT&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-09T01:29:40.739Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06919666", "title": "NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Cancer", "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "NT219", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2025-06-12", "completion_date": "2031-02", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-09-09T01:29:40.739Z", "location_count": 2, "location_summary": "Aurora, Colorado • Highlands Ranch, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Highlands Ranch", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06919666" }, { "nct_id": "NCT04129151", "title": "Palbociclib + Ganitumab In Ewing Sarcoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ewing Sarcoma", "Ewing's Sarcoma Recurrent" ], "interventions": [ { "name": "Palbociclib", "type": "DRUG" }, { "name": "Ganitumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "12 Years to 50 Years" }, "enrollment_count": 10, "start_date": "2019-12-05", "completion_date": "2022-12-15", "has_results": true, "last_update_posted_date": "2024-08-01", "last_synced_at": "2026-09-09T01:29:40.739Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04129151" }, { "nct_id": "NCT03811886", "title": "Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pulmonary Metastatic Osteosarcoma (pOS)" ], "interventions": [ { "name": "Natalizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "5 Years to 30 Years" }, "enrollment_count": 0, "start_date": "2024-12-01", "completion_date": "2026-10-01", "has_results": false, "last_update_posted_date": "2025-01-15", "last_synced_at": "2026-09-09T01:29:40.739Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03811886" }, { "nct_id": "NCT00003166", "title": "Bryostatin and Vincristine in B-Cell Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Multiple Myeloma", "Stage III Multiple Myeloma" ], "interventions": [ { "name": "bryostatin 1", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "1998-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-11", "last_synced_at": "2026-09-09T01:29:40.739Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003166" }, { "nct_id": "NCT00794781", "title": "A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "E6201", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2008-06-22", "completion_date": "2015-10-15", "has_results": false, "last_update_posted_date": "2022-10-14", "last_synced_at": "2026-09-09T01:29:40.739Z", "location_count": 12, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Las Vegas, Nevada + 9 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "Albany", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00794781" }, { "nct_id": "NCT04825288", "title": "XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Phase I: XB2001 250 mg", "type": "BIOLOGICAL" }, { "name": "Phase I: XB2001 500 mg", "type": "BIOLOGICAL" }, { "name": "Phase I: XB2001 1000 mg", "type": "BIOLOGICAL" }, { "name": "Phase II: XB2001 1000 mg", "type": "BIOLOGICAL" }, { "name": "Phase II: Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "XBiotech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 76, "start_date": "2021-05-27", "completion_date": "2025-06-10", "has_results": true, "last_update_posted_date": "2026-08-04", "last_synced_at": "2026-09-09T01:29:40.739Z", "location_count": 30, "location_summary": "Tucson, Arizona • Burbank, California • Cerritos, California + 26 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Cerritos", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04825288" }, { "nct_id": "NCT03635164", "title": "Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Stereotactic Body Radiation Therapy (SBRT)", "type": "RADIATION" }, { "name": "Standard of Care Therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2018-11-12", "completion_date": "2023-05-02", "has_results": false, "last_update_posted_date": "2025-06-27", "last_synced_at": "2026-09-09T01:29:40.739Z", "location_count": 3, "location_summary": "Aurora, Colorado • Colorado Springs, Colorado • Fort Collins, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Fort Collins", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03635164" }, { "nct_id": "NCT04282044", "title": "Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult", "Triple Negative Breast Cancer", "Colorectal Cancer", "Hepatocellular Carcinoma", "Osteosarcoma", "Epithelial Ovarian Cancer", "Gastric Cancer", "Non-small Cell Lung Cancer", "Malignant Melanoma" ], "interventions": [ { "name": "CRX100 suspension for infusion", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "COMBINATION_PRODUCT" }, { "name": "Cyclophosphamide", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "BIOLOGICAL", "COMBINATION_PRODUCT" ], "sponsor": "BioEclipse Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2021-01-08", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2024-02-08", "last_synced_at": "2026-09-09T01:29:40.739Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • La Jolla, California • Stanford, California", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04282044" }, { "nct_id": "NCT04024800", "title": "Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Triple-negative Breast Cancer" ], "interventions": [ { "name": "AE37 Peptide vaccine", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "NuGenerex Immuno-Oncology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 29, "start_date": "2019-05-03", "completion_date": "2024-06-30", "has_results": false, "last_update_posted_date": "2021-06-02", "last_synced_at": "2026-09-09T01:29:40.739Z", "location_count": 6, "location_summary": "Decatur, Illinois • Effingham, Illinois • Swansea, Illinois + 3 more", "locations": [ { "city": "Decatur", "state": "Illinois" }, { "city": "Effingham", "state": "Illinois" }, { "city": "Swansea", "state": "Illinois" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04024800" }, { "nct_id": "NCT01455532", "title": "A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasm Malignant" ], "interventions": [ { "name": "Iniparib (SAR240550-BSI-201)", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Placlitaxel", "type": "DRUG" }, { "name": "Pegylated liposomal doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2011-11", "completion_date": "2014-04", "has_results": false, "last_update_posted_date": "2014-10-22", "last_synced_at": "2026-09-09T01:29:40.739Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Augusta, Georgia + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Augusta", "state": "Georgia" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01455532" } ] }